Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
A Phase I Study of DE-766 (nimotuzumab) with Concurrent Chemoradiotherapy in Locally Advanced Esophageal Cancer
jRCT2080221282Phase 1
- Sponsor
- Daiichi Sankyo Co., Ltd.
- Start
- Oct 2010
- Modality
- Monoclonal Antibodies → Antibody-Based Therapeutics
- Countries
- 1
01
Overview
Phase 1, open-label, single-arm trial of nimotuzumab in esophageal cancer, sponsored by Daiichi Sankyo Co., Ltd.
02
Drugs
nimotuzumab
03
Conditions
esophageal cancer
Beyond the preview
Go deeper on jRCT2080221282.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on jRCT2080221282.